Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The thymus is believed to play an important role in the pathogenesis of myasthenia gravis (MG). The 80% of MG patients with anti-acetylcholine receptor autoantibodies fall into three clinical subgroups: 1) thymoma; 2) early-onset MG (<age of 40; EOMG) and 3) late-onset (LOMG; onset after 40). Thymectomy is widely used in EOMG, but its benefits have not been established in randomized controlled trials. A multicenter international trial (MGTX) currently seeks to determine whether thymectomy reduces corticosteroid requirements, and to look for correlations with thymic histology. We here describe the validated, standardized histological workup and reporting system used in this trial.

Original publication

DOI

10.1016/j.jneuroim.2008.06.017

Type

Journal article

Journal

J Neuroimmunol

Publication Date

15/09/2008

Volume

201-202

Pages

64 - 73

Keywords

Adolescent, Adult, Age Factors, Aging, Child, Female, Humans, Immunohistochemistry, Male, Myasthenia Gravis, Randomized Controlled Trials as Topic, Reproducibility of Results, Sex Factors, Thymectomy, Thymoma, Thymus Extracts, Thymus Gland, Thymus Neoplasms